Skip to main content
SpringerLink
Log in

Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma

  • Short Communications
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Summary

Ten patients with advanced renal carcinoma were treated by ifosfamide (50–60 mg/kg/dayx5 days). The treatment was repeated every 4 weeks and continued until progression appeared. Two patients came into partial remission, two had subjective improvement, and six did not respond.

Seven patients developed acute psychopathological symptoms during the first ifosfamide-cycle. Five patients had visual and paranoid hallucinations, four patients were completely confused. Follow-up for up to 10 weeks showed a persisting organic brain syndrome in five patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Allen LM, Creaven PJ (1975) Pharmacokinetics of ifosfamide. Clin Pharmacol Ther 17:492–498

    PubMed  Google Scholar 

  2. Creaven PJ, Allen LM, Alford DA, Cohen MH (1974) Clinical pharmacology of isophosphamide. Clin Pharmacol Ther 16:77–86

    PubMed  Google Scholar 

  3. Hartwich G, Neidhardt B, Lutz H (1978) Klinische Erfahrungen mit Holoxan im Rahmen einer sequentiellen Kombinationstherapie. Med Klin 73:1247–1252

    PubMed  Google Scholar 

  4. Hoefer-Janker H, Scheef W, Günther U, Hüls W (1975) Erfahrungen mit der fraktionierten Ifosfamid-Stoßtherapie bei generalisierten malignen tumoren. Med Welt 26:972–979

    PubMed  Google Scholar 

  5. Ritter S, Schröder HJ (1977) Klinische Erfahrungen mit dem Zytostatikum Ifosfamid. Med Welt 28:1395–1400

    PubMed  Google Scholar 

  6. Schmoll HJ (1977) Effects and side effects of ifosfamide in metastasing testicular tumors: monotherapy and combination therapy. Int Holoxan Symp Proc 121–127, Düsseldorf

  7. Schnitker J, Brock N, Burkert H, Fichtner E (1976) Auswertung einer kooperativen klinischen Prüfung des Zytostatikums Ifosfamid. Arzneim Forsch (Drug Res) 26:1–32

    Google Scholar 

  8. Talley RW (1973) Chemotherapy of adenocarcinoma of the kidney. Cancer 32:1062–1065

    PubMed  Google Scholar 

  9. Tucker WG (1977) Ifosfamide in the treatment of lung cancer. Int Holoxan Symp Proc 132–137, Düsseldorf

Download references

Author information

Authors and Affiliations

  1. Onkologisches Zentrum, Fakultät für klinische Medizin Mannheim der Universität Heidelberg, Theodor-Kutzer-Ufer, D-6800, Mannheim, Federal Republic of Germany

    M. E. Heim, R. Fiene, E. Schick, E. Wolpert & W. Queißer

Authors
  1. M. E. Heim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Fiene
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Schick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Wolpert
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W. Queißer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heim, M.E., Fiene, R., Schick, E. et al. Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma. J Cancer Res Clin Oncol 100, 113–116 (1981). https://doi.org/10.1007/BF00405909

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00405909

Key words

Search

Navigation